Group 1 - Beijing Kexing Holdings' subsidiary has received re-registration approval for its combined hepatitis A and B vaccine, Beierlaifu, which is the only approved combined vaccine in China [1][2] - Since its launch in 2005, over 13 million doses of Beierlaifu have been administered across 29 provinces and cities in China [1] - Viral hepatitis poses a significant public health threat in China and globally, with hepatitis B causing direct medical costs and indirect losses exceeding 100 billion yuan annually [1] Group 2 - The inclusion of hepatitis A and B in the national immunization program has led to significant progress in disease control, with the combined vaccine playing a crucial role in achieving the goal of eliminating viral hepatitis as a public health threat by 2030 [2]
国产甲型乙型肝炎联合疫苗获批再注册上市